• 1
    Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F, et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003; 23: 440448.
  • 2
    Albillos A, Hera Ad Ade L, Reyes E, Monserrat J, Munoz L, Nieto M, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004; 40: 624631.
  • 3
    Heller J, Sogni P, Barriere E, Tazi KA, Chauvelot-Moachon L, Guimont MC, et al. Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376381.
  • 4
    Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006: 45: 280289.
  • 5
    Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004; 21: 210221.
  • 6
    Perales J, Angel Lasuncion M, Cano A, Martin-Scapa MA, Maties M, Herrera E. Changes in the lipid profile in chronic hepatopathies [in Spanish]. Med Clin (Barc) 1994; 102: 364368.
  • 7
    Zambon S, Orlando R, Sartore G, Bassi A, Manzato E, Crepaldi G. The lipoprotein composition of plasma and ascitic fluid in liver cirrhosis. Eur J Clin Invest 1995; 25: 143148.
  • 8
    Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90: 1204012044.
  • 9
    Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995; 126: 548558.
  • 10
    McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 2003; 20: 551557.
  • 11
    Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 16011608.
  • 12
    Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004; 113: 509513.
  • 13
    Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999; 117: 12221228.
  • 14
    Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003; 13: 226231.
  • 15
    Ramirez MJ, Ibanez A, Navasa M, Casals E, Morales-Ruiz M, Jimenez W, et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. J Hepatol 2004; 40: 424430.
  • 16
    Lebrec D. Animal models in portal hypertension. In: Portal Hypertension: Clinical and Physiological Aspects. Tokyo, Japan: Springer-Verlag; 1991: 101113.
  • 17
    Casas AT, Hubsch AP, Doran JE. Effects of reconstituted high-density lipoprotein in persistent gram-negative bacteremia. Am Surg 1996; 62: 350355.
  • 18
    Cue JI, DiPiro JT, Brunner LJ, Doran JE, Blankenship ME, Mansberger AR, et al. Reconstituted high density lipoprotein inhibits physiologic and tumor necrosis factor alpha responses to lipopolysaccharide in rabbits. Arch Surg 1994; 129: 193197.
  • 19
    Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J. Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. HEPATOLOGY 2003; 38: 13781383.
  • 20
    Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986; 90: 12321240.
  • 21
    Lee SS, Hadengue A, Girod C, Braillon A, Lebrec D. Reduction of intrahepatic vascular space in the pathogenesis of portal hypertension. In vitro and in vivo studies in the rat. Gastroenterology 1987; 93: 157161.
  • 22
    Miller LL. Technique of isolated rat liver perfusion. In: Isolated Liver Perfusion and Its Applications. New York, NY: Raven; 1973: 1152.
  • 23
    Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20: 470475.
  • 24
    Leglise D. Commission de standardisation de l'ARCOL recommandations pratiques pour le dosage du HDL-C après précipitation par le phosphotungstate de sodium et le chlorure de magnésium. Inf Sci Biol 1996; 49( suppl.): 26.
  • 25
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248254.
  • 26
    Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69: 28212828.
  • 27
    Kitchens RL, Wolfbauer G, Albers JJ, Munford RS. Plasma lipoproteins promote the release of bacterial lipopolysaccharide from the monocyte cell surface. J Biol Chem 1999; 274: 3411634122.
  • 28
    Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 14291431.
  • 29
    Lamping N, Dettmer R, Schroder NW, Pfeil D, Hallatschek W, Burger R, et al. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 1998; 101: 20652071.
  • 30
    Heumann D, Lauener R, Ryffel B. The dual role of LBP and CD14 in response to gram-negative bacteria or gram-negative compounds. J Endotoxin Res 2003; 9: 381384.
  • 31
    Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 16081610.
  • 32
    Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469487.
  • 33
    Pavanato A, Tunon MJ, Sanchez-Campos S, Marroni CA, Llesuy S, Gonzalez-Gallego J, et al. Effects of quercetin on liver damage in rats with carbon tetrachloride-induced cirrhosis. Dig Dis Sci 2003; 48: 824829.
  • 34
    Matsunaga T, Nakajima T, Miyazaki T, Koyama I, Hokari S, Inoue I, et al. Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells. Metabolism 2003; 52: 4249.
  • 35
    Lee CM, Chien CT, Chang PY, Hsieh MY, Jui HY, Liau CS, et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005; 183: 251258.
  • 36
    Paterno R, Ruocco A, Postiglione A, Hubsch A, Andresen I, Lang MG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004; 17: 204211.
  • 37
    Robbesyn F, Garcia V, Auge N, Vieira O, Frisach MF, Salvayre R, et al. HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003; 17: 743745.
  • 38
    Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson CB, et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 1997; 100: 439448.
  • 39
    Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002; 35: 478491.
  • 40
    Michel JB, Feron O, Sase K, Prabhakar P, Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 2590725912.
  • 41
    Shah V, Cao S, Hendrickson H, Yao J, Katusic ZS. Regulation of hepatic eNOS by caveolin and calmodulin after bile duct ligation in rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G1209G1216.
  • 42
    Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897905.
  • 43
    Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 12231233.
  • 44
    Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002; 166: 514517.
  • 45
    Lei MG, Morrison DC. Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages. Infect Immun 2000; 68: 50845089.
  • 46
    Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271: 518520.
  • 47
    Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000; 275: 1127811283.
  • 48
    Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11: 952958.
  • 49
    Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004; 126: 749755.
  • 50
    Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 10041010.
  • 51
    Ji H, Jiang JY, Xu Z, Kroeger EA, Lee SS, Liu H, et al. Change in lipid profile and impairment of endothelium-dependent relaxation of blood vessels in rats after bile duct ligation. Life Sci 2003; 73: 12531263.
  • 52
    Sewnath ME, Levels HH, Oude Elferink R, van Noorden CJ, ten Kate FJ, van Deventer SJ, et al. Endotoxin-induced mortality in bile duct-ligated rats after administration of reconstituted high-density lipoprotein. HEPATOLOGY 2000; 32: 12891299.
  • 53
    Cockerill GW, McDonald MC, Mota-Filipe H, Cuzzocrea S, Miller NE, Thiemermann C. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. FASEB J 2001; 15: 19411952.